Risk Factors of Anxiety and Depression in Patients With Herpes Zoster Neuralgia
Risk Factors Analysis of Anxiety and Depression in Patients With Herpes Zoster Neuralgia and Characteristics of Serum Biomarkers and Functional Brain Magnetic Resonance Changes
1 other identifier
observational
600
1 country
1
Brief Summary
The goal of this observational study is to explore risk factors of anxiety and depression in patients with herpes zoster neuralgia, and the changes of certain serum biomarkers and functional brain magnetic resonance images of these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 19, 2024
CompletedFirst Posted
Study publicly available on registry
June 10, 2024
CompletedStudy Start
First participant enrolled
June 21, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
ExpectedAugust 26, 2024
August 1, 2024
1.9 years
May 19, 2024
August 23, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
HADS score
Enrolled patients will be first evaluated by Hospital Anxiety and Depression Scare questionaire and according to the HADS score, patients will be divided to group with anxiety/depression and group without anxiety/depression.
during hospital stay, average of 1 week
Secondary Outcomes (9)
Interleukin (IL）-1β plasma level
during hospital stay, average of 1 week
IL-2 receptor plasma level
during hospital stay, average of 1 week
IL-6 plasma level
during hospital stay, average of 1 week
IL-8 plasma level
during hospital stay, average of 1 week
IL-10 plasma level
during hospital stay, average of 1 week
- +4 more secondary outcomes
Study Arms (4)
patients with anxiety
Patients in this group suffered from herpes zoster neuralgia and had a score more than or equal to 8 for Hospital Anxiety and Depression Scale- Anxiety questionnaire.
patients without anxiety
Patients in this group suffered from herpes zoster neuralgia and had a score less than 8 for Hospital Anxiety and Depression Scale- Anxiety questionnaire.
patients with depression
Patients in this group suffered from herpes zoster neuralgia and had a score more than or equal to 8 for Hospital Anxiety and Depression Scale- Depression questionnaire.
patients without depression
Patients in this group suffered from herpes zoster neuralgia and had a score less than 8 for Hospital Anxiety and Depression Scale- Depression questionnaire.
Interventions
Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
Eligibility Criteria
This study will be conducted in patients who are diagnosed as herpes zoster neuralgia
You may qualify if:
- Age more than 18 years old
- Diagnosed as herpes zoster neuralgia
- Signing informed consent
You may not qualify if:
- Unable to complete the scale assessment
- History of mental illness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tongji hospital
Wuhan, Hubei, 430031, China
Related Publications (1)
Du J, Sun G, Ma H, Xiang P, Guo Y, Deng Y, Li S, Li X. Prevalence and Risk Factors of Anxiety and Depression in Patients with Postherpetic Neuralgia: A Retrospective Study. Dermatology. 2021;237(6):891-895. doi: 10.1159/000512190. Epub 2020 Dec 16.
PMID: 33326962BACKGROUND
Biospecimen
Serum is obtained to test for biomarkers
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yang Shuguang, M.D
Tongji medical college of Huazhong University of Science and technology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Deputy director of anesthesiology
Study Record Dates
First Submitted
May 19, 2024
First Posted
June 10, 2024
Study Start
June 21, 2024
Primary Completion
May 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
August 26, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share
no plan to make individual participant data (IPD) available to other researchers